Publication | Closed Access

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

MedicineImmunologyPharmacokinetic StudyTherapeutic EfficacyAntibody EngineeringImmunotherapyOncologyRadiation OncologyHumanized Monoclonal AntibodyαVβ3 Integrin Receptor